NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated
NervGen is fixing some numbers in its past financial reports. The company says the fixes do not change how much cash it has or its business plans.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.